Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma

Lin, Che-Kuang; Lin, Tung-Yi; Lee, Hsi‐Chang; Chen, Kuan-Yang; Liao, Li‐Ying; Ting, Chin-Tsung; Wang, Chung-Kwe

doi:10.1016/j.jcrpr.2015.03.001

Cited by 6 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The details and reasons for exclusion requiring consensus between the authors are described in http://onlinelibrary.wiley.com/doi/10.1002/hep.29883/suppinfo. Finally, 18 studies reporting PH versus TACE in BCLC stage B or stage C patients were included in the systematic review and meta‐analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Eighteen trials (one RCT, five PSM NRCTs, and 12 NRCTs) consisting of 20 data sets and a total of 5,986 patients were included in the meta‐analysis. The RCT was a single‐center trial conducted in China .…”

Section: Resultsmentioning

confidence: 99%

“…The details and reasons for exclusion requiring consensus between the authors are described in Supporting Table S4. Finally, 18 studies (10,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) reporting PH versus TACE in BCLC stage B or stage C patients were included in the systematic review and meta-analysis.…”

Section: Search and Study Selectionmentioning

confidence: 99%

“…(10) A further 17 NRCTs were performed in Spain (one NRCT), Korea (two NRCTs), China (three PSM NRCTs, seven NRCTs), Taiwan (one PSM NRCT, two NRCTs), and Japan (one PSM NRCT). Nine studies (17,20,21,23,27,29,30,32,33) with 3,457 patients included BCLC stage B patients, and another nine trials (11 data sets) (18,19,22,(24)(25)(26)28,30,31) with 3,051 patients enrolled BCLC stage C patients. All trials were published between 2010 and 2017.…”

Section: Study Demographics and Quality Of Evidencementioning

confidence: 99%

See 3 more Smart Citations

Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Search and Study Selectionmentioning

confidence: 99%

Section: Study Demographics and Quality Of Evidencementioning

confidence: 99%

See 2 more Smart Citations

Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For patients with BCLC stage B, TACE was recommended as the rst-line treatment. HCC patients with BCLC stage B who received TACE treatment had shorter mOS (16 to 42 months) than patients undergoing surgery (23 to 70 months) [6,[14][15][16][17]. However, HCC patients with TACE have high recurrence due to incomplete embolization.…”

Section: Discussionmentioning

confidence: 99%

The Trends and Efficacy of Operation in the Treatment of Hepatocellular Carcinoma

Chen

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundOperation for the treatment of hepatocellular carcinoma (HCC) is limited. Recently, the possibility was advanced that operation (including surgery, transplantation, and ablation et, al) could be applied in HCC patients more widely. To address this issue, the trend in the use of operation and surgery for the treatment of HCC with time was analyzed. Additionally, whether patients gain a better survival benefit from surgery than other treatments was also evaluated.MethodsData from SEER registries were used to analyze the trends in the use operation and surgery for HCC and the survival benefits of these procedures. The study included patients between the ages of 35 and 84 years diagnosed as HCC between 2004 and 2015 (n=64019). Propensity score matching (PSM) analysis was used to reduce selection bias.Results From 2004 to 2015, the rate of operation for HCC decreased in the localized group (P<0.001), the regional and distant group (P<0.001). Surgery rate in the localized, regional, and distant group also declined (P=0.016, P=0.009, and P=0.018, respectively). Non-operation rate increased in the localized, regional, and distant group (all P<0.001). The median overall survival (mOS) of patients in the localized, regional group who underwent surgery was longer than that of patients with non-surgery operation and non-operation. Similar survival results were obtained in the analysis of patients with single tumor larger than 5 cm and 2-3 tumors larger than 3 cm. ConclusionAlthough surgery rate declined from 2004 to 2015 in all HCC patients, it might be used more widely in patients with localized and regional tumors. And the treatment of surgery in patients with single tumor larger than 5 cm or patients with 2-3 tumors larger than 3 cm was worth trying.

show abstract

The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study

Wang

Lin²,

Lin³

et al. 2021

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma

Cited by 6 publications

References 25 publications

Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies

Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies

The Trends and Efficacy of Operation in the Treatment of Hepatocellular Carcinoma

The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study

Contact Info

Product

Resources

About